Skip to main content
Terug
DSKYF logo

Daiichi Sankyo Company, Limited

Datakwaliteit: 100%
DSKYF
OTC Healthcare Drug Manufacturers - General
€ 17,70
▼ € 2,20 (-11,06%)
Marktkapitalisatie: 32,76B
Ook genoteerd als DSNKY OTC
Dagbereik
€ 17,70 € 18,30
52-Weeksbereik
€ 16,81 € 29,15
Volume
379
50D / 200D Gem.
€ 19,37 / € 22,56
Vorige Slotkoers
€ 19,90

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 17,9 3,7
Net Margin % 15,7 3,8
Rev Growth 5Y % 18,3 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 341,34
€ 320,76 – € 390,50
 3400 B 3
FY2029 € 276,96
€ 260,26 – € 316,85
 3000 B 3
FY2028 € 228,10
€ 214,35 – € 260,95
 2600 B 4

Belangrijkste Punten

Revenue grew 18,32% annually over 5 years — strong growth
Earnings grew 47,34% over the past year
ROE of 17,86% — decent returns on equity
Net margin of 15,68% shows strong profitability
Debt/Equity of 0,06 — conservative balance sheet
Negative free cash flow of -134,03B

Groei

Revenue Growth (5Y)
18,32%
Revenue (1Y)17,77%
Earnings (1Y)47,34%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
17,86%
ROIC14,43%
Net Margin15,68%
Op. Margin17,60%

Veiligheid

Debt / Equity
0,06
Current Ratio2,53
Interest Coverage28,00

Waardering

P/E Ratio
0,11
P/B Ratio0,02
EV/EBITDA-1,52
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17,77% Revenue Growth (3Y) 21,47%
Earnings Growth (1Y) 47,34% Earnings Growth (3Y) 64,58%
Revenue Growth (5Y) 18,32% Earnings Growth (5Y) 40,47%
Profitability
Revenue (TTM) 1,89T Net Income (TTM) 295,76B
ROE 17,86% ROA 8,56%
Gross Margin 77,96% Operating Margin 17,60%
Net Margin 15,68% Free Cash Flow (TTM) -134,03B
ROIC 14,43% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,06 Current Ratio 2,53
Interest Coverage 28,00 Dividend Yield 0,02%
Valuation
P/E Ratio 0,11 P/B Ratio 0,02
P/S Ratio 0,02 PEG Ratio 0,43
EV/EBITDA -1,52 Dividend Yield 0,02%
Market Cap 32,76B Enterprise Value -505,74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,89T 1,60T 1,28T 1,04T 962,52B
Net Income 295,76B 200,73B 109,19B 66,97B 75,96B
EPS (Diluted) 155,87 104,62 56,91 34,91 39,11
Gross Profit 1,47T 1,19T 914,95B 682,09B 624,23B
Operating Income 331,93B 211,59B 120,58B 73,03B 63,80B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,46T 3,46T 2,51T 2,22T 2,09T
Total Liabilities 1,83T 1,77T 1,06T 864,87B 807,03B
Shareholders' Equity 1,62T 1,69T 1,45T 1,35T 1,27T
Total Debt 101,33B 101,71B 192,86B 213,62B 183,83B
Cash & Equivalents 639,84B 647,18B 334,83B 550,18B 294,80B
Current Assets 1,91T 2,17T 1,50T 1,35T 1,27T
Current Liabilities 754,03B 723,40B 530,26B 395,27B 353,57B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#337 of 618
32
Custom Contrarian Investing (David Dreman)
#618 of 670
5
Value Defensive Investing (Benjamin Graham)
#579 of 709
10

Recente Activiteit

Ingestapt Contrarian Investing (David Dreman)
Mar 25, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 25, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026